STAT3 and neoplasm: Studies using pharmacological approaches, siRNA technology, Mx1-Cre, CD4-Cre or Ncr1-iCreTg mice to abrogate STAT3 signaling in immune cells further confirmed that STAT3 impairs anti-tumor immunity.